Cutera, Inc. (NASDAQ:CUTR) had its target price raised by analysts at Roth Capital from $41.00 to $47.00 in a research note issued to investors on Tuesday. The brokerage currently has a “buy” rating on the medical device company’s stock. Roth Capital’s price objective would suggest a potential upside of 16.05% from the company’s previous close.

Several other equities research analysts have also recently commented on CUTR. BidaskClub raised shares of Cutera from a “hold” rating to a “buy” rating in a research report on Saturday, August 12th. TheStreet raised shares of Cutera from a “c” rating to a “b” rating in a research report on Friday, August 18th. Gabelli reaffirmed a “buy” rating on shares of Cutera in a research report on Wednesday, August 9th. Zacks Investment Research cut shares of Cutera from a “buy” rating to a “hold” rating in a research report on Monday, June 26th. Finally, Sidoti reaffirmed a “buy” rating and issued a $30.00 price objective (up from $27.00) on shares of Cutera in a research report on Saturday, June 3rd. Six analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and a consensus price target of $35.25.

Shares of Cutera (NASDAQ:CUTR) traded up 1.63% during trading on Tuesday, reaching $40.50. The company had a trading volume of 274,286 shares. Cutera has a 12-month low of $10.54 and a 12-month high of $41.15. The company has a market cap of $567.20 million, a P/E ratio of 87.10 and a beta of 0.52. The firm has a 50-day moving average of $32.67 and a 200-day moving average of $24.83.

Cutera (NASDAQ:CUTR) last posted its quarterly earnings data on Monday, August 7th. The medical device company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.03 by $0.10. The business had revenue of $36.40 million for the quarter, compared to analysts’ expectations of $32.08 million. Cutera had a net margin of 5.07% and a return on equity of 11.64%. The firm’s revenue was up 32.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.07 EPS. On average, equities research analysts anticipate that Cutera will post $0.52 EPS for the current year.

Cutera declared that its board has initiated a stock buyback plan on Monday, August 7th that allows the company to buyback $25.00 million in shares. This buyback authorization allows the medical device company to reacquire up to 6.8% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s board believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: “Cutera, Inc. (CUTR) PT Raised to $47.00 at Roth Capital” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/12/cutera-inc-cutr-pt-raised-to-47-00-at-roth-capital.html.

In other news, EVP Miguel Pardos sold 5,000 shares of the stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $36.00, for a total transaction of $180,000.00. Following the completion of the sale, the executive vice president now directly owns 39,698 shares in the company, valued at $1,429,128. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director David A. Gollnick sold 10,000 shares of the stock in a transaction on Monday, June 26th. The stock was sold at an average price of $25.08, for a total transaction of $250,800.00. Following the sale, the director now owns 26,641 shares of the company’s stock, valued at $668,156.28. The disclosure for this sale can be found here. Insiders have sold 61,034 shares of company stock valued at $1,983,017 in the last ninety days. Insiders own 3.30% of the company’s stock.

Large investors have recently bought and sold shares of the business. Morgan Stanley grew its holdings in Cutera by 23.3% in the first quarter. Morgan Stanley now owns 67,345 shares of the medical device company’s stock worth $1,395,000 after purchasing an additional 12,734 shares during the period. Scout Investments Inc. acquired a new position in shares of Cutera during the second quarter valued at about $1,454,000. Driehaus Capital Management LLC acquired a new position in shares of Cutera during the first quarter valued at about $363,000. Kennedy Capital Management Inc. acquired a new position in shares of Cutera during the second quarter valued at about $9,426,000. Finally, Insight Capital Research & Management Inc. acquired a new position in shares of Cutera during the second quarter valued at about $797,000. Institutional investors and hedge funds own 89.15% of the company’s stock.

About Cutera

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Receive News & Stock Ratings for Cutera Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera Inc. and related stocks with our FREE daily email newsletter.